BTIG Research Reaffirms Buy Rating for Tvardi Therapeutics (NASDAQ:TVRD)

Tvardi Therapeutics (NASDAQ:TVRD)‘s stock had its “buy” rating reaffirmed by stock analysts at BTIG Research in a research report issued on Wednesday,Benzinga reports. They currently have a $15.00 price target on the stock. BTIG Research’s price objective points to a potential upside of 400.00% from the stock’s previous close.

Several other equities analysts have also issued reports on TVRD. Weiss Ratings reiterated a “sell (e)” rating on shares of Tvardi Therapeutics in a report on Monday, December 29th. Lucid Cap Mkts upgraded shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. Finally, Wall Street Zen upgraded shares of Tvardi Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, March 8th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $55.50.

Tvardi Therapeutics Trading Down 5.7%

TVRD stock opened at $3.00 on Wednesday. Tvardi Therapeutics has a 1-year low of $2.81 and a 1-year high of $43.65. The firm has a market cap of $28.14 million, a PE ratio of -0.54 and a beta of 0.14. The stock has a 50-day moving average price of $3.78 and a 200-day moving average price of $8.96.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its earnings results on Tuesday, March 31st. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.23).

Hedge Funds Weigh In On Tvardi Therapeutics

A number of large investors have recently bought and sold shares of TVRD. JPMorgan Chase & Co. purchased a new stake in shares of Tvardi Therapeutics in the 2nd quarter worth about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at approximately $43,000. Headlands Technologies LLC bought a new stake in Tvardi Therapeutics during the second quarter valued at $80,000. New York State Common Retirement Fund bought a new position in shares of Tvardi Therapeutics during the second quarter worth about $92,000. Finally, Arax Advisory Partners grew its position in Tvardi Therapeutics by 277.2% in the 4th quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock valued at $36,000 after buying an additional 6,173 shares in the last quarter. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.